Can Viatris’ Revived Revatio Bid In Pediatric PAH Overcome Past Obstacles To US FDA Approval?
Executive Summary
Behind FDA’s decision to call, and then to call off, an advisory committee for pediatric use of Viatris’ Revatio (sildenafil) in pulmonary arterial hypertension lies a debate going back more than a decade, review documents show.